EP1032374A1 - Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen - Google Patents

Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen

Info

Publication number
EP1032374A1
EP1032374A1 EP98954683A EP98954683A EP1032374A1 EP 1032374 A1 EP1032374 A1 EP 1032374A1 EP 98954683 A EP98954683 A EP 98954683A EP 98954683 A EP98954683 A EP 98954683A EP 1032374 A1 EP1032374 A1 EP 1032374A1
Authority
EP
European Patent Office
Prior art keywords
spheroids
active ingredient
spheroids according
coating
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98954683A
Other languages
English (en)
French (fr)
Other versions
EP1032374B1 (de
Inventor
Patrice Debregeas
Gérard LeDuc
Pascal Oury
Pascal Suplie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethypharm SAS
Original Assignee
Ethypharm SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm SAS filed Critical Ethypharm SAS
Priority to SI9830492T priority Critical patent/SI1032374T1/xx
Publication of EP1032374A1 publication Critical patent/EP1032374A1/de
Application granted granted Critical
Publication of EP1032374B1 publication Critical patent/EP1032374B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the present invention relates to a new galemic form in the form of spheroids, containing one or more active ingredients with the exception of tiagabine.
  • the present invention further extends to the process for the preparation of such spheroids and to the multiparticulate pharmaceutical preparations containing these spheroids.
  • These pharmaceutical preparations are intended for the delivery of the spheroids which they contain, and are characterized by the absence of an alteration in the release profile of the active ingredient (s) contained in the spheroids.
  • spheroids is understood to mean spherical units the size of which can vary from 0.25 mm to 3 mm, preferably from 0.5 mm to 1 mm.
  • US Patent 4,684,516 describes tablets for oral administration which disintegrate rapidly in an aqueous medium, which comprise coated granules capable of releasing an active principle at a controlled speed for several hours in the intestinal tract, and which comprise 2 to 15% by weight of binding agents and lubricants.
  • US Pat. No. 4,684,516 describes in particular granules obtained by applying a layer of active principle on non-similar, these granules then being coated with a first film containing a mixture of stearic acid, carnauba wax and talc, and a second film is disintegrating agents such as starch, cellulose or algic acid - which also serve to ensure the cohesion of the tablet.
  • Patent application EP 468 436 describes prolonged-release tablets obtained by compression an active principle and a mixture of two powders, one being hydrophobic and the other water-soluble.
  • the hydrophobic powder is obtained by melting and spraying a mixture of stearic acid, glycerin and hydrogenated castor oil.
  • the water-soluble powder is a cellulose mixed with lactose.
  • Patent application EP 548 356 describes ultiparticulate tablets with rapid disintegration which comprise an active substance in the form of single crystals or microgranules.
  • These tablets are obtained by prior granulation of a mixture of excipients consisting of one or more disintegrating agents, of the carboxymethylcellulose or polyvinylpyrrolidone type, of one or more swelling agents, of the starch type, and of a direct compression sugar. like dextrose.
  • the microgranules or single crystals are dry integrated into the mixture of excipients before being compressed.
  • the granules of the prior art are diluted with auxiliary substances, the role of which is to absorb the physical stresses linked to the compression (binding agents) and to allow the disintegration of the tablet (disintegrating agents) in a liquid medium, ie in aqueous solution or in the digestive fluid.
  • the prior art tablet formulations use auxiliary substances added to the granules during compression to avoid cracking of these granules on the surface.
  • the object of the present invention relates to spheroids containing one or more active ingredients with the exception of tiagabine, which can be compressed directly, without the addition of a substantial part of an auxiliary substance, ie less than 5% by weight, preferably less than 1% by weight.
  • the subject of the present invention is spheroids containing one or more active principles, with the exception of tiagabine, comprising:
  • a core and / or a layer coating said core containing at least one thermoplastic excipient, the consistency of which is pasty to semi-solid at a temperature of the order of 20 ° C., and the melting temperature of which is between approximately 25 ° C and approximately 100 ° C, coated with a flexible and deformable film, based on a polymeric material, in particular a film whose glass transition temperature is less than approximately 30 ° C, which provides either protection, be the masking of taste, that is the modified and controlled release of the active ingredient (s).
  • the core can be composed in particular of a mixture of sucrose and starch or microcrystalline cellulose.
  • thermoplastic excipients is understood to mean compounds having a melting point of between 25 and 100 ° C. and characterized by a pasty to semi-solid consistency at a temperature of the order of 20 ° C.
  • thermoplastic excipients The role of thermoplastic excipients is, in particular, during a possible compression step, to allow the spheroids to deform plastically, and thus to absorb part of the stresses which they undergo, so that their surface is not not cracked or torn.
  • the excipients can be advantageously chosen from partially hydrogenated oils, beeswax, carnauba wax, paraffin waxes, silicone waxes, fatty alcohols and C12-C18 fatty acids, semi-synthetic glycerides solids, monoester diesters or triesters of glycerol, polyoxyethylene glycols, glycosylated polyoxyethylene glycerides, and mixtures thereof.
  • the layer containing at least one thermoplastic excipient is coated with a flexible and deformable film, comprising a polymeric material, the glass transition temperature of which is less than approximately 30 ° C, preferably less than approximately 20 ° C.
  • the polymeric film comprises a polymeric material which is either a polymer or a mixture of at least one polymer and a plasticizer. The polymer film can be used, depending on the case, to protect the active ingredient from the environment.
  • the polymer is preferably an acrylic, vinyl or cellulosic polymer or copolymer.
  • Plasticizer is understood to mean a product which makes it possible to reduce the glass transition temperature of the polymer.
  • the plasticizer is preferably chosen from triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, triacetin, diethyl phthalate, polyethylene glycols, polysorbates, mono- and diacetylated glycerides, and their mixtures.
  • the mechanical properties of the polymer film in particular the percentage of elongation and the breaking strength 0, can serve as criteria for selecting the polymer and / or the plasticizer. These mechanical characteristics can also be determined by the method described in standards DIN53 455 and ISO / RI 184.
  • a polymer or a polymer / plasticizer mixture having a percentage of elongation greater than about 50% is preferably chosen for coating spheroids intended to be compressed.
  • the Eudragit NE30D® 0 polymer sold by the company ROHM which is a neutral copolymer of acrylic and methacrylic acid esters in the form of an aqueous dispersion at 30%, has a percentage elongation of 600% and a breaking strength equal to 8 N / mm 2 which makes it particularly flexible and deformable.
  • the active ingredient (s) are dispersed in the mass of the nucleus.
  • the active ingredient (s) are dispersed in the layer containing at least one thermoplastic excipient.
  • the active ingredient (s) are applied to the surface of the core, then covered with a layer containing at least one thermoplastic excipient.
  • the active principle can be protected, in one of the four preceding variants, by associating it with an antioxidant agent and / or by coating it with a protective film.
  • the active ingredient (s) are dispersed in the mass of the core and in the layer containing at least one thermoplastic excipient.
  • the spheroids according to the invention can advantageously be coated with a water-dispersible outer layer.
  • the outer layer ensures the cohesion of said spheroids during a possible compression step, and ensures the disintegration in an aqueous medium of the tablet obtained.
  • the water-dispersible outer layer is preferably made of an acrylic, vinyl or cellulosic polymer.
  • the present invention also relates to the process for the preparation of the spheroids described above.
  • the manufacturing of the cores can be carried out by turbine assembly from calibrated sucrose crystals, or by extrusion-spheronization.
  • the active principle can be mixed with the extruded-spheronized mass.
  • the layer containing at least one thermoplastic excipient, the film containing a polymeric material, and optionally the external protective layer are successively deposited on the cores by spraying, in a granulation turbine, in a turbine. perforated, in a fluidized air bed or by any other suitable means.
  • the method according to the invention comprises two or three stages depending on whether it is desired to prepare spheroids comprising an external layer which is hydrodispersible or not.
  • Spheroids having a water-dispersible outer layer are particularly suitable for the preparation of tablets.
  • the first step consists in depositing the thermoplastic excipient (s) on the cores.
  • the assembly preparation can be, as the case may be, in the form of solid dispersions in aqueous or organic media, in the form of solutions, in the form of emulsions, or in the molten state.
  • the active principle is dispersed in the mass of the layer containing at least one excipient thermoplastic, the active ingredient is incorporated in the assembly preparation.
  • the active principle can be fixed by dusting on the neutral cores previously wetted with the mounting preparation.
  • the second step of the process according to the invention consists in depositing the polymer film making it possible to ensure the protection of the active principle, the masking of taste or the modified release of the active principle.
  • the polymeric coating preparation can be in the form of solutions or dispersions in an aqueous or organic medium.
  • the optional third step of the process according to the invention consists in depositing the external protective layer by spraying the coating preparation which can be in the form of a solution or dispersion in an aqueous or organic medium.
  • an anti-adhering agent such as talc, a plasticizer such as polyethylene glycol, an antioxidant agent such as dl-alpha-tocopherol.
  • a disintegrating agent can advantageously be added to the outer protective layer so as to accelerate the release of the spheroids in an aqueous medium, when these have been compressed.
  • the disintegrating agent is for example crosslinked carboxymethylcellulose, crosslinked polyvinylpyrrolidone or sodium carboxymethyl starch.
  • the present invention also relates to the mul tiparticular pharmaceutical preparations containing the spheroids described above which can be obtained by the process of the invention.
  • the multiparticulate pharmaceutical preparations according to the invention are preferably without the form of capsules filled with said spheroids, or tablets of said spheroids.
  • Said tablets are advantageously prepared without the substantial addition of auxiliary substances. Up to 5% by weight of a lubricating agent such as talc can be added to the spheroids before compression.
  • Said tablets advantageously comprise spheroids protected by a water-dispersible layer consisting of an acrylic, vinyl, cellulosic polymer or a water-dispersible thermoplastic excipient, or any other excipient soluble in an aqueous medium.
  • This layer has the role of ensuring the cohesion of the spheroids between them, thus ensuring the hardness of the tablet, and of allowing the tablet to disintegrate when it is immersed in solution.
  • the tablets according to the invention are dispersible in solution and restore independent spheroids, so that the release profile of the tablet and of the spheroids which constitute it are practically equivalent. Indeed, the tablets according to the invention allow the delivery of spheroids without the release profile of the active ingredient (s) they contain is altered by compression.
  • the tablets according to the invention can be composed only of the spheroids according to the invention or of a mixture of spheroids and placebos spheroids, that is to say spheroids conform to the present invention but devoid of active principle.
  • the stresses exerted on the spheroids, during the compression step, can vary from 5 N to 50 kN but preferably between 5 kN and 15 kN.
  • the hardness of the tablets is preferably between 10 N and 100 N, more preferably between 10 N and 50 N.
  • the disintegration time of the tablets in an aqueous medium at 37 ° C. is less than 60 min.
  • the tablets according to the invention preferably have a mass of between 0.1 g and 1 g.
  • Their shape can be round, oval, oblong, have a flat or concave surface, and have engravings or score bars.
  • the tablets according to the invention can be the subject of a final protective or coloring coating.
  • the single figure represents the mass percentage of in vitro dissolution of a particular active principle, isosorbide mononitrate, for the spheroids according to the invention not compressed (curve 1) and for a tablet of spheroids according to the invention (curve 2) .
  • Precirol® is a thermoplastic compound which, by softening and spreading in contact with the charge maintained at 50 ° C, will form a uniform film around the cores.
  • talc can be added to Précirol®.
  • the spheroid mixture is compressed on a Frogerais OA alternative press.
  • the active ingredient is dosed by ultraviolet spectrophotometry.
  • NP-PHARM in a coating turbine, a perforated turbine or a fluidized air bed
  • Example 2 Place a fraction of the microgranules obtained according to Example 1 in a perforated turbine or a fluidized air bed,
  • the spheroids are then compressed on a rotary instrumented machine of the Fette P1200 type.
  • the compressive forces applied are between 10 kN and 30 kN.
  • the active principle is dosed by HPLC at the wavelength 285 nm.
  • Talc 14.74 g. Mix the powders (use a cubic or planetary mixer).
  • the spheroids are then compressed on a rotary instrumented machine of the Fette P1200 type.
  • the compression forces applied are between 10 KN and 30 KN.
  • Pallet dissolution device in accordance with the standard (USP XXIII, ⁇ 711> device 2). Medium 500 ml, Purified water at 37 ° C. Stirring speed 100 revolutions / minute. The active principle is dosed by UV continuously at wavelengths: 285-320 nm.
EP98954683A 1997-11-21 1998-11-19 Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen Expired - Lifetime EP1032374B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9830492T SI1032374T1 (en) 1997-11-21 1998-11-19 Spheroids, preparation method and pharmaceutical compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714631A FR2771291B1 (fr) 1997-11-21 1997-11-21 Spheroides, procede de preparation et compositions pharmaceutiques
FR9714631 1997-11-21
PCT/IB1998/001911 WO1999026608A1 (fr) 1997-11-21 1998-11-19 Spheroides, procede de preparation et compositions pharmaceutiques

Publications (2)

Publication Number Publication Date
EP1032374A1 true EP1032374A1 (de) 2000-09-06
EP1032374B1 EP1032374B1 (de) 2003-08-06

Family

ID=9513635

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98954683A Expired - Lifetime EP1032374B1 (de) 1997-11-21 1998-11-19 Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen

Country Status (29)

Country Link
US (1) US6077544A (de)
EP (1) EP1032374B1 (de)
JP (1) JP2001523706A (de)
KR (1) KR100502938B1 (de)
CN (1) CN1223341C (de)
AT (1) ATE246496T1 (de)
AU (1) AU744580B2 (de)
BG (1) BG65117B1 (de)
BR (1) BR9814672A (de)
CA (1) CA2310147C (de)
CZ (1) CZ299110B6 (de)
DE (1) DE69817010T2 (de)
DK (1) DK1032374T3 (de)
EA (1) EA003324B1 (de)
ES (1) ES2203989T3 (de)
FR (1) FR2771291B1 (de)
HR (1) HRP20000323B1 (de)
HU (1) HU230053B1 (de)
IL (2) IL136215A0 (de)
MX (1) MXPA00004959A (de)
NO (1) NO329728B1 (de)
NZ (1) NZ504662A (de)
PL (1) PL193878B1 (de)
PT (1) PT1032374E (de)
SK (1) SK284493B6 (de)
TR (1) TR200002130T2 (de)
WO (1) WO1999026608A1 (de)
YU (1) YU31000A (de)
ZA (1) ZA9810631B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046647A1 (fr) 2003-11-10 2005-05-26 Ethypharm Comprimes faiblement doses a reseau de polymeres

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
CN1190185C (zh) 1999-04-06 2005-02-23 埃迪克埃迪法姆药品实验室 可饮用布洛芬药物悬浮液
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
DK1414956T3 (da) 2001-06-22 2008-03-03 Genencor Int Höjt påvirkningsresistente granula
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
FR2845289B1 (fr) * 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
NZ523946A (en) 2003-01-31 2004-06-25 Carl Ernest Alexander Portable hygiene compositions comprising a semi-solid gel and active ingredients in bead form for use in personal oral, dental or skin care
ES2221804B1 (es) * 2003-06-18 2006-04-01 Lipofoods, S.L. Microcapsulas para la administracion de ingredientes activos.
WO2005034923A1 (en) * 2003-10-10 2005-04-21 Ethypharm Sustained-release microgranules containing gingko biloba extract and the process for manufacturing these
ATE378042T1 (de) * 2004-04-12 2007-11-15 Pfizer Prod Inc Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) * 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
WO2008065504A1 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
EP2468263A1 (de) 2010-12-23 2012-06-27 Laboratorios Del. Dr. Esteve, S.A. Komprimierte feste Darreichungsformen
CN112118920B (zh) 2018-05-11 2023-04-14 斯多里机械有限责任公司 驱动组件
WO2019217607A2 (en) 2018-05-11 2019-11-14 Stolle Machinery Company, Llc Infeed assembly quick change features
CN112154037B (zh) 2018-05-11 2022-12-13 斯多里机械有限责任公司 快速更换工具组件
US11208271B2 (en) 2018-05-11 2021-12-28 Stolle Machinery Company, Llc Quick change transfer assembly
CN115673132A (zh) 2018-05-11 2023-02-03 斯多里机械有限责任公司 成型站和缩颈机
EP3791168A4 (de) 2018-05-11 2021-08-18 Stolle Machinery Company, LLC Anordnung zur kompletten inspektion der einspeisungsbaugruppe
JP7312196B2 (ja) 2018-05-11 2023-07-20 ストール マシーナリ カンパニー，エルエルシー 回転マニホールド
US11420242B2 (en) 2019-08-16 2022-08-23 Stolle Machinery Company, Llc Reformer assembly

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
NZ230763A (en) * 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
FR2679451B1 (fr) * 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
DE69405752T2 (de) * 1993-06-14 1998-02-05 Janssen Pharmaceutica Nv Filmbeschichtete tablette von astemizol und pseudoephedrin mit verlängerter freigabe
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9926608A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046647A1 (fr) 2003-11-10 2005-05-26 Ethypharm Comprimes faiblement doses a reseau de polymeres

Also Published As

Publication number Publication date
CA2310147C (fr) 2010-05-25
IL136215A (en) 2006-12-31
EA003324B1 (ru) 2003-04-24
KR100502938B1 (ko) 2005-07-25
HUP0100562A2 (hu) 2002-05-29
MXPA00004959A (es) 2002-10-17
NO20002605D0 (no) 2000-05-19
PL193878B1 (pl) 2007-03-30
DE69817010T2 (de) 2004-05-27
ZA9810631B (en) 1999-05-24
NZ504662A (en) 2002-09-27
FR2771291A1 (fr) 1999-05-28
DK1032374T3 (da) 2003-11-24
WO1999026608A1 (fr) 1999-06-03
PT1032374E (pt) 2003-12-31
EA200000548A1 (ru) 2000-12-25
BR9814672A (pt) 2000-10-03
HUP0100562A3 (en) 2002-08-28
YU31000A (sh) 2002-11-15
JP2001523706A (ja) 2001-11-27
CZ299110B6 (cs) 2008-04-23
CA2310147A1 (fr) 1999-06-03
BG104511A (en) 2001-04-30
ATE246496T1 (de) 2003-08-15
CZ20001849A3 (cs) 2000-10-11
AU744580B2 (en) 2002-02-28
FR2771291B1 (fr) 2000-02-25
DE69817010D1 (de) 2003-09-11
PL340659A1 (en) 2001-02-12
SK284493B6 (sk) 2005-05-05
HRP20000323B1 (en) 2006-07-31
ES2203989T3 (es) 2004-04-16
HU230053B1 (hu) 2015-06-29
CN1223341C (zh) 2005-10-19
EP1032374B1 (de) 2003-08-06
NO329728B1 (no) 2010-12-06
KR20010032329A (ko) 2001-04-16
AU1170499A (en) 1999-06-15
HRP20000323A2 (en) 2001-06-30
US6077544A (en) 2000-06-20
TR200002130T2 (tr) 2000-12-21
NO20002605L (no) 2000-07-05
IL136215A0 (en) 2001-05-20
SK7562000A3 (en) 2001-06-11
CN1282239A (zh) 2001-01-31
BG65117B1 (bg) 2007-03-30

Similar Documents

Publication Publication Date Title
EP1032374B1 (de) Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen
CA2483212C (fr) Particules enrobees a liberation prolongee et comprimes les contenant
FR2771292A1 (fr) Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
WO2003077888A2 (fr) Comprimes a base de microcapsules a liberation modifiee
CA2721232C (fr) Forme orale solide dotee d'un double profil de liberation comprenant des multiparticules
EP1549298B1 (de) Sphäroide, deren herstellungsverfahren und sphäroidenhaltige arzneimittel
WO1997023219A1 (fr) Microgranules a liberation prolongee contenant du diltiazem comme principe actif
WO1998035663A1 (fr) Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique
EP1515704B1 (de) Mikrokapseln für die verzögerte kontrollierte freisetzung von perindopril
WO2000025749A9 (fr) Utilisation de gommes xanthanes pour la preparation de compositions pharmaceutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000613

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: MK PAYMENT 20000613;RO PAYMENT 20000613;SI PAYMENT 20000613

17Q First examination report despatched

Effective date: 20001201

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: FRENCH

REF Corresponds to:

Ref document number: 69817010

Country of ref document: DE

Date of ref document: 20030911

Kind code of ref document: P

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ETHYPHARM

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MOINAS & SAVOYE SA

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030404004

Country of ref document: GR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031119

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: ETHYPHARM

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2203989

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040507

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20171020

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20171024

Year of fee payment: 20

Ref country code: DK

Payment date: 20171020

Year of fee payment: 20

Ref country code: FI

Payment date: 20171020

Year of fee payment: 20

Ref country code: DE

Payment date: 20171019

Year of fee payment: 20

Ref country code: FR

Payment date: 20171020

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20171020

Year of fee payment: 20

Ref country code: BE

Payment date: 20171020

Year of fee payment: 20

Ref country code: GR

Payment date: 20171020

Year of fee payment: 20

Ref country code: NL

Payment date: 20171024

Year of fee payment: 20

Ref country code: ES

Payment date: 20171204

Year of fee payment: 20

Ref country code: IT

Payment date: 20171020

Year of fee payment: 20

Ref country code: PT

Payment date: 20171102

Year of fee payment: 20

Ref country code: CH

Payment date: 20171025

Year of fee payment: 20

Ref country code: IE

Payment date: 20171020

Year of fee payment: 20

Ref country code: GB

Payment date: 20171020

Year of fee payment: 20

Ref country code: SE

Payment date: 20171024

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69817010

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20181118

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20181119

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20181118

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20181119

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 246496

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181119

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181118

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20201110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181120